2. Baseline characteristics of patients in included studies.
| Avacincaptad pegol phase 2/3 (GATHER1)a | CLG561 ± LFG316 phase 2 | Eculizumab phase 2 (COMPLETE)b | Lampalizumab phase 2 (MAHALO) | Lampalizumab phase 3 (CHROMA and SPECTRI) | LFG316/tesidolumab phase 2 | Pegcetacoplan phase 2 (FILLY) | Pegcetacoplan phase 3 (DERBY and OAKS) | |
| ITT population, N | 286 | 114 | 30 | 129 | 1881 | 158 | 246 | 1208 |
| Mean age, years | 79 | 78 | 80 | 79 | 78 | 79 | 80 | 78 |
| Female, % | 70 | 59 | 52 | 44 | 60 | 61 | 63 | 61 |
| White ethnicity, % | 98 | 65 | NA | 98 | 97 | NA | 98 | 93 |
| Bilateral GA, % | 99 | NA | 60 | 100 | 100 | NA | 84 | NA |
| nAMD in fellow eye, % | 0 | 0 | 0 | 0 | 0 | 0 | 38 | NA |
| Mean GA lesion size at baseline, mm2 | 7.6 | NA | 6.4 | 8.7 | 8.1 | NA | 8.4 | 8.3 |
| Extrafoveal GA lesion, % | 95 | NA | NA | NA | 48 | NA | NA | 39 |
| Unifocal GA lesion, % | NA | NA | NA | NA | 22 | NA | NA | 30 |
| Mean BCVA at baseline, ETDRS letters | 69 | NA | 74 | 48 | 66 | 43 | 34 | 59 |
aThere were no available baseline characteristics for the 1 mg intervention group of the avacincaptad pegol phase 2/3 study.
bThe percentage of female participants was estimated from the enrolled population (n = 60), as this metric was unavailable for the analysed population (n = 30) of the eculizumab phase 2 study.
Abbreviations: BCVA = best‐corrected visual acuity; ETDRS = early treatment for diabetic retinopathy; GA = geographic atrophy; ITT = intention‐to‐treat; NA = not available.